The treatment of COVAN is typically supportive with interventions including dietary sodium restriction of 2.3 g/day, optimization of hyperlipidemia and hypertension, blockade of the renin-angiotensin-aldosterone system, sodium/glucose cotransporter-2 inhibition, and maintenance of euvolemia. This evidence concerns the gene SLC5A2 and hyperlipidemia.